Low LeverageVery low financial leverage materially reduces near-term solvency risk and gives management flexibility to fund development through equity or strategic deals. This structural balance-sheet conservatism supports continued R&D and trial activity without heavy interest burdens.

Large Equity Base / Capitalization EventsSubstantial increases in equity provide a multi-year runway potential and reduce immediate refinancing pressure, enabling the company to pursue development milestones and regulatory steps. A stronger capital base structurally lowers short-term liquidity default risk.

Very Lean HeadcountAn eight-person workforce implies a low fixed-cost base and a lean operating model, allowing flexible outsourcing of trials and commercialization. Over months, this structural nimbleness can limit payroll-driven burn and allocate cash to R&D or milestone-driven spending.

Bears Say

Persistent Operating Cash BurnConsistent negative operating cash flow across multiple years shows the business consumes cash to run operations and fund development. Structurally, this creates reliance on external financing, exposing the company to dilution or funding gaps if capital markets tighten before cash generation improves.

Deep, Volatile Losses And RevenuesPersistent large operating and net losses, combined with highly volatile revenue, indicate the company has not achieved stable commercial traction or operating leverage. Over the medium term, negative margins and revenue inconsistency undermine prospects for sustained profitability and scalable cash generation.

Negative Returns On EquityRepeated negative ROE reflects that capital raised has not translated into positive earnings, signaling value dilution for shareholders. Structurally poor capital efficiency complicates future fundraising economics and raises questions about long-term allocation of investor capital.

1NP1 FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was €3.15 and its highest was €4.21 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is €252.51M.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

InDex Pharmaceuticals Holding AB’s upcoming earnings report date is Apr 15, 2026 which is in 55 days.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Jan 21, 2026. The company reported -€0.657 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.657.

Is InDex Pharmaceuticals Holding AB overvalued?

According to Wall Street analysts InDex Pharmaceuticals Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 77,455,960 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -€0.657 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.773%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in DE:1NP1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InDex Pharmaceuticals Holding AB

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. It seeks to invest in biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.